

RECEIVED
CENTRAL FAX CENTER

OCT 25 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

Facsimile Transmission

To:	Name:	USPTO Central Fax
	Company:	
	Fax Number:	571-273-8300
	Voice Phone:	
From:	Name:	Dr. Philip C. Njemanze
	Voice Phone:	234(80)33026124

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Date and time of transmission: Tuesday, October 25, 2005 5:07:36 PM
Number of pages including this cover sheet: 02



CHIDICON MEDICAL CENTER

INTERNATIONAL INSTITUTES OF ADVANCED RESEARCH & TRAINING

October 24th, 2005.

Prince Dr Philip C. Njemanze
MD (suma cum Laudae)
Chairman

Examiner D. L. Jones
Supervisor: Thurman Page

US Patent Application: 10/635,820

Art Unit: 1618

Dear Madam,

No. 1 Uratta/MCC Road,
P. O. Box 302. Owerri,
Imo State, Nigeria.
Tel.: +234(80)33026124
Tel.: +234(83)231183
eFax: 1(321)600-7726
Email:
philip.njemanze@chidicon.com
www.chidicon.com
www.chidicon.org
chidicon@chidiconinc.com
www.chidiconinc.com

Election of Species

In reference to your communication dated 6/29/2005 I elected for examination Page 2 paragraph 2, Option II Claims 9-13, drawn to a method and system for controlling infectious diseases as set forth in independent claim 9, classified in class 424, subclass 9.1+. In response to your communication dated September 29th, 2005.

I have elected the species of hydrophobic active agent such as antiviral agent as set forth in claim 10; a hydrophilic active agent such as a cytokine as set forth in claim 12; tissue specific peptide such as an antibody as set forth in claim 12; therapeutically active agent such as a vaccine as set forth in claims 9 and 12; targeted cells using a nucleoside such as set forth in claims 9 and 12; infectious disease such as viral disease as set forth in claims 10 and 13.

Thanks in anticipation.

Yours truly,

Dr Philip C. Njemanze MD